Original Study| Volume 17, ISSUE 6, P530-534, June 01, 2016

Central Nervous System-Acting Medicines and Risk of Hospital Admission for Confusion, Delirium, or Dementia



      Most studies assessing the effect of central nervous system (CNS)-acting medicines on cognitive disturbances have focused on the use of individual medicines. The impact on cognitive function when another CNS-acting medicine is added to a patient's treatment regimen is not well known.


      To determine risk of hospitalization for confusion, delirium, or dementia in older people associated with increasing numbers of CNS-acting medicines taken concurrently, as well as the number of standard doses taken each day (measured as defined daily doses).


      Retrospective cohort study, from July 2011 to June 2012, using health claims data.


      Australian veteran population.


      A total of 74,321 community-dwelling individuals aged 65 years and over, who were dispensed at least 1 CNS-acting medicine in the year before study entry. Patients with prior hospitalization for confusion or delirium, and those with dementia or receiving palliative care, were excluded.

      Main outcome measure

      Hospitalization for confusion, delirium, or dementia.


      Over the 1-year study period, 401 participants were hospitalized with confusion, delirium, or dementia. Adjusted analyses showed the risk of hospitalization was 2.4 times greater with the use of 2 CNS-acting medicines compared with no use [incident rate ratio (IRR) 2.39, 95% confidence interval (CI) 1.79–3.19, P < .001], and more than 19 times greater when 5 or more CNS-acting medicines were taken concurrently (IRR 19.35, 95% CI 11.10–33.72, P < .001). Similarly, the risk of hospitalization was significantly increased among patients taking between 1.0 and 1.9 standard doses per day (IRR 2.64, 95% CI 1.99–3.50, P < .001) and between 2.0 and 2.9 standard doses per day (IRR 3.43, 95% CI 2.07–5.69, P < .001) compared with no use.


      Use of multiple CNS-acting medicines or higher doses is associated with an increased risk of hospitalization for confusion, delirium, or dementia. Health care professionals need to be alert to the contribution of CNS-acting medicines among patients presenting with confusion or delirium and consider strategies to reduce treatment burden where possible.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Voyer P.
        • Cohen D.
        • Lauzon S.
        • Collin J.
        Factors associated with psychotropic drug use among community-dwelling older persons: A review of empirical studies.
        BMC Nurs. 2004; 3: 3
        • Ruths S.
        • Straand J.
        • Nygaard H.
        Psychotropic drug use in nursing homes—Diagnostic indications and variations between institutions.
        Eur J Clin Pharmacol. 2001; 57: 523-528
        • Snowden J.
        • Galanos D.
        • Vaswani D.
        A 2009 survey of psychotropic medication use in Sydney nursing homes.
        Med J Aust. 2011; 194: 270-271
        • Ravera S.
        • Visser S.T.
        • de Gier J.J.
        • de Jong-van den Berg L.T.
        Prevalence, cumulative incidence, monotherapy and combination therapy, and treatment duration of frequently prescribed psychoactive medications in The Netherlands: Retrospective database analysis for the years 2000 to 2005.
        Clin Ther. 2010; 32: 2457-2466
        • Rikala M.
        • Korhonen M.J.
        • Sulkava R.
        • Hartikainen S.
        Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users.
        Eur J Clin Pharmacol. 2011; 67: 731-739
        • Kjosavik S.R.
        • Ruths S.
        • Hunskaar S.
        Psychotropic drug use in the Norwegian general population in 2005: Data from the Norwegian Prescription Database.
        Pharmacoepidemiol Drug Saf. 2009; 18: 572-578
        • Lasserre A.
        • Younès N.
        • Blanchon T.
        • et al.
        Psychotropic drug use among older people in general practice: Discrepancies between opinion and practice.
        Br J Gen Pract. 2010; 60: e156-e162
        • Manthey L.
        • van Veen T.
        • Giltay E.J.
        • et al.
        Correlates of (inappropriate) benzodiazepine use: The Netherlands Study of Depression and Anxiety (NESDA).
        Br J Clin Pharmacol. 2011; 71: 263-272
        • Gadzhanova S.
        • Bell J.S.
        • Roughead E.E.
        What analgesics do older people use prior to initiating oxycodone for non-cancer pain? A retrospective database study.
        Drugs Aging. 2013; 30: 921-926
        • Gaudreau J.D.
        • Gagnon P.
        • Roy M.A.
        • Harel F.
        • Tremblay A.
        Association between psychoactive medications and delirium in hospitalized patients: A critical review.
        Psychosomatics. 2005; 46: 302-316
        • Gray S.L.
        • Lai K.V.
        • Larson E.B.
        Drug-induced cognition disorders in the elderly.
        Drug Saf. 1999; 21: 101-122
        • Billioti de Gage S.
        • Moride Y.
        • Ducruet T.
        • et al.
        Benzodiazepine use and risk of Alzheimer’s disease: Case-control study.
        BMJ. 2014; 349: g5205
        • Hsiao F.Y.
        • Peng L.N.
        • Lin M.H.
        • Chen L.K.
        Dose-responsive effect of psychotropic drug use and subsequent dementia: A nationwide propensity score matched case-control study in Taiwan.
        J Am Med Dir Assoc. 2014; 15: 509-513
        • Wright R.M.
        • Roumani Y.F.
        • Boudreau R.
        • et al.
        Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: Findings from the Health, Aging and Body Composition study.
        J Am Geriatr Soc. 2009; 57: 243-250
        • Puustinen J.
        • Nurminen J.
        • Löppönen M.
        • et al.
        Use of CNS medications and cognitive decline in the aged: A longitudinal population-based study.
        BMC Geriatr. 2011; 11: 70
        • Rothberg M.B.
        • Herzig S.J.
        • Pekow P.S.
        • et al.
        Association between sedating medications and delirium in older inpatients.
        J Am Geriatr Soc. 2013; 61: 923-930
        • Kalisch L.M.
        • Caughey G.E.
        • Barratt J.D.
        • et al.
        Prevalence of preventable medication-related hospitalizations in Australia: An opportunity to reduce harm.
        Int J Qual Health Care. 2012; 24: 239-249
      1. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2015. Available at: Accessed September 3, 2015.

        • National Centre for Classification in Health
        International statistical classification of diseases and related health problems, Tenth Revision, Australian Modification (ICD-10-AM).
        National Centre for Classification in Health, Faculty of Health Sciences, University of Sydney, Sydney2004
      2. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2015. Oslo, 2014. Available at: Accessed September 3, 2015

        • Pottegård A.
        • Hallas J.
        Assigning exposure duration to single prescriptions by use of the waiting time distribution.
        Pharmacoepidemiol Drug Saf. 2013; 22: 803-809
        • Aarsland D.
        • Zaccai J.
        • Brayne C.
        A systematic review of prevalence studies of dementia in Parkinson's disease.
        Mov Disord. 2005; 20: 1255-1263
      3. Australian Bureau of Statistics. Technical paper: Socio-Economic Indexes for Areas (SEIFA), 2011. ABS Cat. no. 2033.0.55.001. Canberra: Commonwealth of Australia, 2013. Available at:$File/2033.0.55.001%20seifa%202011%20technical%20paper.pdf. Accessed September 3, 2015.

        • Vitry A.
        • Wong S.A.
        • Roughead E.E.
        • et al.
        Validity of medication-based co-morbidity indices in the Australian elderly population.
        Aust N Z J Public Health. 2009; 33: 126-130
        • Best O.
        • Gnjidic D.
        • Hilmer S.N.
        • et al.
        Investigating polypharmacy and drug burden index in hospitalised older people.
        Intern Med J. 2013; 43: 912-918
        • Siddiqi N.
        • House A.O.
        • Holmes J.D.
        Occurrence and outcome of delirium in medical in-patients: A systematic literature review.
        Age Ageing. 2006; 35: 350-364
        • Young J.
        • Inouye S.K.
        Delirium in older people.
        BMJ. 2007; 334: 842-846
        • Australian Institute of Health and Welfare
        Dementia in Australia.
        (Cat. no. AGE 70) AIHW, Canberra2012 (Available at:) (Accessed September 3, 2015)
        • Roughead E.E.
        • Gilbert A.L.
        • Woodward M.C.
        Medication use by Australian war veterans in residential aged-care facilities.
        J Pharm Pract Res. 2008; 38: 14-18
        • Culp K.
        • Tripp-Reimer T.
        • Wadle K.
        • et al.
        Screening for acute confusion in elderly long-term care residents.
        J Neurosci Nurs. 1997; 29: 95-100
        • Grimmsmann T.
        • Himmel W.
        Discrepancies between prescribed and defined daily doses: A matter of patients or drug classes?.
        Eur J Clin Pharmacol. 2011; 67: 847-854
        • Australian Institute of Health and Welfare
        Health care usage and costs: A comparison of veterans and war widows and widowers with the rest of the community.
        (Cat. no. PHE 42) AIHW, Canberra2002 (Available at:) (Accessed September 3, 2015)